Top in ID: Monkeypox vaccine eligibility; bivalent COVID-19 boosters
Click Here to Manage Email Alerts
The White House recently announced plans to expand monkeypox vaccination eligibility in the United States.
The monkeypox vaccine is now available to anyone who has been at a venue where the illness has been reported and to men who have sex with men who have had multiple sex partners in a venue where there is known to have been monkeypox or in an area where it is spreading. It was the top story in infectious disease last week.
Another top story was about an announcement from the FDA that COVID-19 vaccine manufacturers should add a spike protein component for omicron subvariants to existing vaccines to create bivalent boosters. The FDA made the announcement days after an advisory committee voted 19-2 in favor of the change.
Read these and more top stories in infectious disease below:
With cases increasing, US expands access to monkeypox vaccine
U.S. health officials announced a new plan to broaden access to monkeypox vaccines amid a continued rise in cases. Read more.
FDA says vaccine makers should add omicron to COVID-19 boosters
The FDA has told COVID-19 vaccine manufacturers that they should add a spike protein component for the omicron subvariants BA.4 and BA.5 to their existing vaccines to create bivalent boosters. Read more.
FDA advisors vote in favor of adding omicron to COVID-19 boosters
An FDA advisory committee voted to recommend changing the composition of COVID-19 booster vaccines to include the addition of the omicron variant of SARS-CoV-2 as a component. Read more.
Q&A: NIH expands COVID-19 data available to researchers
Recently, the NIH announced that its All of Us Research Program would expand the COVID-19 data that are available to researchers in the United States. Read more.
New data suggest pandemic disruptions led to drop in HIV testing
New data showed a sharp decrease in CDC-funded HIV tests administered in health care and non-health care settings from 2019 to 2020 — primarily among groups disproportionately affected by HIV. Read more.